The Innovative Medicines Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The Innovative Medicines Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Research on the future of medicine should be undertaken in areas where society, public health and the competitiveness objectives of the biomedical industry are aligned and require the pooling of resources and greater concentration. collaboration between the public and private sectors, with the participation of Small and Medium Enterprises. (SMEs).
The objective of the restricted call is to support further research activities in exceptional cases where it is necessary to enable successful consortia to exploit the results of their initial action, move to the next stage of the challenge, and maximize the impact of the results of the initial action.
Beneficiaries | The call is open to legal entities active in the field in question, in particular SMEs; educational institutions; research or technology centres. |
Type of Financing | Contribution to expenditures/co-financing |
Budget in Euros | 11,427,098 euros |
Deadline | 29 September 2020 |